Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0C0LO
|
|||
| Former ID |
DNCL002292
|
|||
| Drug Name |
IMGN529
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C85.9] | Phase 2 | [1] | |
| Metastatic non-hodgkin's lymphoma [ICD-11: 2B33.5; ICD-10: C81-C86, C82-C85] | Phase 1 | [2] | ||
| Company |
ImmunoGen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leukocyte antigen CD37 (CD37) | Target Info | . | [3] |
| KEGG Pathway | Hematopoietic cell lineage | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT01534715) IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. U.S. National Institutes of Health. | |||
| REF 3 | The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model. Leukemia. 2014 Jul;28(7):1501-10. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.